Repare Therapeutics shares MYTHIC trial data, highlighting Lunre+Camo’s tolerability and efficacy in gynecologic cancers with FDA guidance on next steps.
Why Is Repare Therapeutics Stock Trading Lower On Friday?
Where Today's News Shapes Tomorrow
